+

WO1996041813A3 - Polymeres fonctionnalises destines a une ligation dirigee - Google Patents

Polymeres fonctionnalises destines a une ligation dirigee Download PDF

Info

Publication number
WO1996041813A3
WO1996041813A3 PCT/IB1995/001175 IB9501175W WO9641813A3 WO 1996041813 A3 WO1996041813 A3 WO 1996041813A3 IB 9501175 W IB9501175 W IB 9501175W WO 9641813 A3 WO9641813 A3 WO 9641813A3
Authority
WO
WIPO (PCT)
Prior art keywords
functionalized
site
family
topology
aldehyde
Prior art date
Application number
PCT/IB1995/001175
Other languages
English (en)
Other versions
WO1996041813A2 (fr
WO1996041813A9 (fr
Inventor
Robin E Offord
Hubert F Gaertner
Original Assignee
Robin E Offord
Hubert F Gaertner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robin E Offord, Hubert F Gaertner filed Critical Robin E Offord
Priority to EP95944855A priority Critical patent/EP0788375A2/fr
Priority to JP8535165A priority patent/JPH10509208A/ja
Priority to AU73272/96A priority patent/AU7327296A/en
Publication of WO1996041813A2 publication Critical patent/WO1996041813A2/fr
Publication of WO1996041813A3 publication Critical patent/WO1996041813A3/fr
Publication of WO1996041813A9 publication Critical patent/WO1996041813A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

On décrit des polymères organiques, par exemple un poly(éthylène glycol), fonctionnalisé à l'aide d'un groupe amino-oxy formant une oxime, ainsi que des procédés de préparation et d'utilisation de ceux-ci dans une ligation chimiosélective, dirigée, avec une macromolécule cible, ou une surface, fonctionnalisée par un aldéhyde (ou une cétone), dans des conditions de ligation modérées. On décrit également des structures polymères de recombinaison, lesquelles contiennent des multi-polymères, sont fonctionnalisés par amino-oxy ou par un aldéhyde (ou une cétone), et permettent une ligation chimiosélective dirigée, dans des conditions modérées, de la structure de recombinaison (et, ainsi, de tous les polymères de celle-ci) avec un seul site d'une macromolécule cible, via une liaison oxime. On décrit encore des familles de structures de polymères de recombinaison fonctionnalisés, dans lesquelles chaque structure diffère de celles de la même famille quant à sa topologie mais non quant à son poids moléculaire (moyen). Des procédés d'utilisation de ces polymères comprennent la modification systématique d'une macromolécule cible, afin de créer rapidement une famille de molécules cibles, de préférence des protéines biologiquement importantes, différant quant à leur topologie mais non quant à leur poids moléculaire, famille à partir de laquelle on peut identifier des macromolécules possédant les propriétés biologiques ou physiques souhaitées, telles qu'un meilleur comportement pharmacocinétique.
PCT/IB1995/001175 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee WO1996041813A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95944855A EP0788375A2 (fr) 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee
JP8535165A JPH10509208A (ja) 1994-11-09 1995-11-09 部位特異的結合のための官能化されたポリマー
AU73272/96A AU7327296A (en) 1994-11-09 1996-11-09 Functionalized polymers for site-specific attachment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33685094A 1994-11-09 1994-11-09
US08/336,850 1994-11-09
US39469095A 1995-02-23 1995-02-23
US08/394,690 1995-02-23

Publications (3)

Publication Number Publication Date
WO1996041813A2 WO1996041813A2 (fr) 1996-12-27
WO1996041813A3 true WO1996041813A3 (fr) 1997-05-22
WO1996041813A9 WO1996041813A9 (fr) 1997-06-19

Family

ID=26990408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1995/001175 WO1996041813A2 (fr) 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee

Country Status (4)

Country Link
EP (1) EP0788375A2 (fr)
AU (1) AU7327296A (fr)
CA (1) CA2204726A1 (fr)
WO (1) WO1996041813A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US7351855B2 (en) 1992-07-15 2008-04-01 La Jolla Pharmaceutical Company Chemically defined non-polymeric valency platform molecules and conjugates thereof
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525955D0 (en) * 1995-12-19 1996-02-21 Therexsys Ltd Improved pharmaceutical compositions
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
NZ502134A (en) 1997-07-03 2002-03-28 Orquest Inc Polysaccharide therapeutic carrier where first and second polysaccharide is cross linked to each other through oxime bonds between amino groups
FI980489A7 (fi) * 1998-03-04 1999-09-05 Alexei Radievich Khomutov Syklodekstriinien uudet johdannaiset
WO2001048052A1 (fr) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Glycols de polyalkylene ramifies
CA2395713C (fr) 2000-01-10 2012-04-10 Torben Lauesgaard Nissen Produits conjugues g-csf
JP2003521930A (ja) 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第ＶＩＩ因子または第ＶＩＩａ因子様分子
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
AU2002216749A1 (en) * 2000-06-30 2002-01-14 Smithkline Beecham Corporation Chemokine conjugates
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
CN1457257A (zh) * 2000-09-08 2003-11-19 格莱风治疗公司 “拟”天然化学连接
UY26929A1 (es) * 2000-09-29 2002-04-26 Abbott Lab Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
WO2002043770A2 (fr) * 2000-12-01 2002-06-06 Conforma Therapeutic Corporation Multimeres de peptides d'accueil, preparation et utilisations associees
JP4656814B2 (ja) 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
ATE432288T1 (de) 2001-02-27 2009-06-15 Maxygen Aps Neue interferon-beta-ähnliche moleküle
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
RU2362807C2 (ru) 2002-06-21 2009-07-27 Ново Нордиск Хелт Кэр Аг Конъюгат полипептида фактора vii, способ его получения, его применение и содержащая его фармацевтическая композиция
EP1577293B1 (fr) 2002-12-26 2014-06-18 Shionogi Co., Ltd. Procede de purification/concentration de chaine de sucres au moyen d'une molecule de piegeage de chaine de sucres et procede d'analyse de structure de chaine de sucres
WO2004075923A2 (fr) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Conjugues de groupe fonctionnel a facteur polymerique viii
US20040249119A1 (en) * 2003-06-05 2004-12-09 Fox Martin Edward Novel mPEG propionaldehyde precursor
US20080206182A1 (en) * 2003-08-08 2008-08-28 Fresenius Kabi Deutschland Gmbh Conjugates of a Polymer and a Protein Linked by an Oxime Group
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP2641611A3 (fr) 2003-10-17 2013-12-18 Novo Nordisk A/S Thérapie combinée
BRPI0506864A (pt) 2004-01-21 2007-05-29 Novo Nordisk As método para conjugar peptìdeos, peptìdeo conjugado, composto e sais, pró-drogas e solvatos farmaceuticamente aceitáveis destes, composição farmacêutica, uso de um composto, e, método para tratamento de doença
KR20060130182A (ko) 2004-02-02 2006-12-18 암브룩스, 인코포레이티드 변형된 인간 인터페론 폴리펩티드 및 이의 용도
WO2006069220A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Hormone de croissance humaine modifiee
EP3153181A1 (fr) 2004-11-12 2017-04-12 Bayer HealthCare LLC Modification dirigée sur site de fviii bdd
SG161209A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
MX2007007581A (es) 2004-12-22 2007-07-24 Ambrx Inc Composiciones de amino acil-arnt sintetasa y sus usos.
GB2438982A (en) 2004-12-22 2007-12-12 Ambrx Inc Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
CN103030690A (zh) 2005-06-03 2013-04-10 Ambrx公司 经改良人类干扰素分子和其用途
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
BRPI0615351A2 (pt) * 2005-08-30 2011-05-17 Novo Nordisk Healthcare Ag formulações lìquidas de hormÈnio do crescimento peguilado
DE602006020480D1 (de) * 2005-11-08 2011-04-14 Ambrx Inc Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
PT2339014E (pt) 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
CA2631491C (fr) 2005-12-14 2015-02-24 Ambrx, Inc. Compositions contenant des acides amines et polypeptides non naturels, procedes mettant en jeu ceux-ci et utilisations de ceux-ci
JP2009537609A (ja) 2006-05-24 2009-10-29 ノボ ノルディスク ヘルス ケア アーゲー 延長されたｆｉｘアナログ及び誘導体
CA2655188A1 (fr) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag Nouveaux conjugues de proteines et leurs procedes de preparation
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
AU2007292893B2 (en) 2006-09-08 2012-03-01 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
EP2275202A1 (fr) * 2008-03-13 2011-01-19 Ajinomoto Co., Inc. Substance d'élimination de composé carbonyle
AU2009274076C1 (en) 2008-07-23 2014-04-17 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
EP3216800A1 (fr) 2008-09-26 2017-09-13 Ambrx, Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
HUE036343T2 (hu) 2008-09-26 2018-07-30 Ambrx Inc Nem-természetes aminosav replikáció-függõ mikroorganizmusok és vakcinák
CN102369209B (zh) 2009-03-20 2015-06-10 韩美科学株式会社 制备特异性位点生理活性多肽结合物的方法
US8067526B2 (en) 2009-03-27 2011-11-29 Nof Corporation Method for producing polyoxalkylene derivative
KR101832937B1 (ko) * 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (fr) 2009-07-27 2016-11-16 Baxalta GmbH Conjugués de protéines de coagulation sanguine
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
EP3815708A1 (fr) 2010-03-05 2021-05-05 Omeros Corporation Molécules chimères inhibitrices de l'activation du complément
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
PL3572091T3 (pl) 2010-08-17 2024-07-29 Ambrx, Inc. Zmodyfikowane polipeptydy relaksyny i ich zastosowania
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US8409526B2 (en) 2010-12-09 2013-04-02 General Electric Company Cellulose substrates, compositions and methods for storage and analysis of biological materials
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
WO2013004607A1 (fr) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Polypeptides de fusion de relaxine et leurs utilisations
KR102172897B1 (ko) 2012-06-08 2020-11-02 서트로 바이오파마, 인크. 부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
EP2859013B1 (fr) * 2012-06-12 2016-08-31 Fina Biosolutions LLC Fonctionnalisation différentielle des polymères avec des réactifs amino oxy pour des dosages diagnostiques
EP2863955B1 (fr) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Protéines de fc modifiées, comprenant des résidus d'acides aminés non naturels spécifiques de site, leurs conjugués, leur préparation et leurs procédés d'utilisation
ES2907763T3 (es) 2012-08-31 2022-04-26 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
EP3019522B1 (fr) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
WO2015054658A1 (fr) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
JP6721572B2 (ja) * 2014-05-23 2020-07-15 ノバルティス アーゲー ジスルフィド含有タンパク質からコンジュゲートを作製するための方法
WO2018148419A1 (fr) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Polypeptides de relaxine modifiés comprenant un activateur pharmacocinétique et leurs utilisations
PT3849614T (pt) 2018-09-11 2024-02-28 Ambrx Inc Conjugados de polipeptídeos de interleucina-2 e suas utilizações
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CA3128081A1 (fr) 2019-02-12 2020-08-20 Ambrx, Inc. Contenant de compositions, procedes et utilisations de conjugues anticorps-agonistes tlr
MX2022011163A (es) 2020-03-11 2022-10-18 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
WO2022040596A1 (fr) 2020-08-20 2022-02-24 Ambrx, Inc. Conjugués anticorps-agonistes de tlr, procédés et utilisations de ceux-ci
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539167A2 (fr) * 1991-10-21 1993-04-28 Ortho Pharmaceutical Corporation Imidates de PEG et leurs dérivés protéiniques
EP0605963A2 (fr) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Réactifs pour la formation de liaisons de peg-hydrazone et peg-oxime et leurs dérives de protein
WO1994025071A1 (fr) * 1993-05-05 1994-11-10 Keith Rose Composes de polyoximes et leur preparation
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539167A2 (fr) * 1991-10-21 1993-04-28 Ortho Pharmaceutical Corporation Imidates de PEG et leurs dérivés protéiniques
EP0605963A2 (fr) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Réactifs pour la formation de liaisons de peg-hydrazone et peg-oxime et leurs dérives de protein
WO1994025071A1 (fr) * 1993-05-05 1994-11-10 Keith Rose Composes de polyoximes et leur preparation
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VILASECA L ET AL: "PROTEIN CONJUGATES OF DEFINED STRUCTURE: SYNTHESIS AND USE OF A NEW CARRIER MOLECULE", BIOCONJUGATE CHEMISTRY, vol. 4, no. 6, 1 November 1993 (1993-11-01), pages 515 - 520, XP000417288 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351855B2 (en) 1992-07-15 2008-04-01 La Jolla Pharmaceutical Company Chemically defined non-polymeric valency platform molecules and conjugates thereof
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Also Published As

Publication number Publication date
WO1996041813A2 (fr) 1996-12-27
CA2204726A1 (fr) 1996-12-27
EP0788375A2 (fr) 1997-08-13
AU7327296A (en) 1997-01-09
EP0788375A3 (fr) 1997-09-17

Similar Documents

Publication Publication Date Title
WO1996041813A3 (fr) Polymeres fonctionnalises destines a une ligation dirigee
WO2003047518A3 (fr) Polymere amphiphile biocompatible greffe avec de la cyclodextrine et methodes de production et d'utilisation
DE502006007655D1 (de) Präparate umfassend hyperverzweigte polymere
WO2001002017A3 (fr) Derives de l'erythropoietine
DE60213380D1 (de) Kontinuierliches verfahren zur herstellung von engeren molekulargewichtverteilungen konjugierten dien-polymeren und dadurch hergestellten produkten
WO2005012364A3 (fr) Matrice complexe a usage biomedical
WO2001032146A3 (fr) Vesicules polymeres amphiphiles
AU6279900A (en) Polymer blends with improved impact resistance
DE60229955D1 (de) Zusammensetzungen, welche stäbchenförmige polymere und nanoröhrenförmige strukturen umfassen, sowie verfahren zur herstellung derselben
EP1054031A3 (fr) Augmentation de la masse moléculaire et modification de polymères de condensation
DE69312700D1 (de) Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
EP1947145A3 (fr) Mélanges de polyesters biodégradables et produits fabriqués à partir de ceux-ci
NO954434D0 (no) Bioaktive og/eller målsökende dendrimer-konjugater
CA2296374A1 (fr) Reticulats polymeres semi-interpenetrants
Zant et al. Synthetic biodegradable hydrogels with excellent mechanical properties and good cell adhesion characteristics obtained by the combinatorial synthesis of photo-cross-linked networks
GB0329825D0 (en) Biological products
WO2005010075A3 (fr) Methode pour preparer des polymeres fonctionnalises a partir d'alcools de polymere
DE60025475D1 (de) Herstellung von polymerteilchen
ATE290564T1 (de) Funktionsfähige poly-alpha-aminosäurederivate zur modifizierung von biologisch wirksamen stoffen und deren herstellung
ATE455831T1 (de) Verbesserte polyolefinbasierende klebharze und verfahren zur herstellung von klebharzen
Kim et al. UV-induced graft copolymerization of monoacrylate-poly (ethylene glycol) onto poly (3-hydroxyoctanoate) to reduce protein adsorption and platelet adhesion
CA2021666A1 (fr) Composition de polymeres thermoplastiques contenant des agents modifiant les caracteristiques rheologiques du produit fondu
WO2001077197A3 (fr) Hydrogels et procedes de preparation associe
Ouchi et al. Mechanical property and biodegradability of solution‐cast films prepared from amphiphilic polylactide‐grafted dextran
WO1999054349A3 (fr) Molecules d'acides nucleiques dermatophagoides, proteines et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2204726

Country of ref document: CA

Ref country code: CA

Ref document number: 2204726

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1995944855

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THERECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1995944855

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995944855

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载